Overview of Diclac ID

Property	Description
Active ingredient	Diclofenac (Sodium diclofenac)
Form	Modified-release tablet (Oral solid dosage form)
Pharmacological class	Nonsteroidal anti-inflammatory drug (NSAID)
General purpose	Anti-inflammatory, analgesic, and antipyretic relief
Origin	Synthetic

What Type of Medicine is Diclac ID?

Diclac ID is a specialized, prescription-only medicine that belongs to the Nonsteroidal anti-inflammatory drug (NSAID) class. Its sole active ingredient is Diclofenac, a widely used synthetic compound classified chemically as a Phenylacetic acid derivative.

As a member of the NSAID pharmacological class, Diclac ID is primarily intended for oral use, acting systemically throughout the body to provide therapeutic relief. The fundamental function of the active ingredient is to inhibit the body's production of substances that cause pain, fever, and inflammation. Diclofenac acts as an analgesic and anti-inflammatory agent for various conditions, such as managing inflammation associated with musculoskeletal discomfort. This action serves the general therapeutic purpose of providing both significant anti-inflammatory and analgesic (pain-relieving) effects, targeting discomfort that arises from inflammatory processes.

Composition and The Dual-Release Tablet Form

Diclac ID is uniquely presented as a modified-release tablet, an Oral solid dosage form. This specific formulation is distinguished by its dual-release technology, which is intended for improving the consistency of the drug's effect over time.

This dual-release mechanism is achieved by combining an immediate-release component and a sustained-release component within a single tablet structure. This intentional design provides a specific delivery profile compared to standard, immediate-release Diclofenac medicines, as it aims for both rapid initial relief and prolonged therapeutic action. The formulation is designed to maintain drug concentrations consistently in the body, allowing for less frequent dosing. This structure provides the general advantage of consistent relief from discomfort, reducing the fluctuations often experienced with conventional dosing.

What side effects are possible with Diclac ID?

Possible Side Effects and Safety Information

The safety profile of Diclac ID, which contains diclofenac, is structured by regulatory authorities based on System-Organ Classes (SOCs) and the frequency of observed adverse reactions. The most commonly documented effects frequently involve the gastrointestinal (GI) and nervous systems, including nausea, diarrhea, abdominal pain, headache, and dizziness, all typically classified as Common.

Adverse reactions that are Rare or Very Rare involve broader and more serious systemic events. Official labeling includes information on potential serious Gastrointestinal Events, such as bleeding, ulceration, or perforation, and serious Cardiovascular Thrombotic Events, including myocardial infarction and stroke, which are risks associated with the Nonsteroidal Anti-inflammatory Drug (NSAID) class.

Specific Safety Constraints are documented for certain populations. Risk for serious adverse events may be higher in older adults, and use is generally restricted or contraindicated for patients with severe hepatic or renal impairment or established congestive heart failure. Regulatory information also notes that the risk for serious thrombotic events may increase with higher dosages and longer duration of use. These classifications are derived from official regulatory documents, providing a neutral overview of the medicine's documented safety profile.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This information is based strictly on the official overdose guidance for diclofenac, the active ingredient in Diclac ID, as documented by government regulatory bodies, and is not a substitute for professional medical assessment.

Required Emergency Actions

Seek immediate medical attention if an overdose is suspected, or go to your nearest hospital casualty department immediately if too much medicine has been taken. Regulatory information states that there is no specific antidote available for diclofenac overdose.

Documented Manifestations and Severe Outcomes

Overdose may not present a typical clinical picture. Manifestations documented in official labels include Headache, Nausea, Vomiting, Dizziness, Disorientation, and Ringing in the ears (Tinnitus).

Severe outcomes that have been documented include life-threatening complications across several systems:

Neurological: Coma and Convulsions (Seizures).
Gastrointestinal: Severe bleeding, ulceration, or perforation.
Organ Failure: Acute Renal Failure and Hepatic Failure.

Officially Described Management

Management is primarily supportive and symptomatic to treat complications like hypotension or convulsions. To prevent further systemic absorption following a recent high-dose ingestion, the medical team may utilize procedures such as Gastric lavage and administration of Activated charcoal.

Population-Specific Note

Regulatory agencies note that the elderly population is at a greater risk for serious adverse reactions to NSAIDs, particularly severe gastrointestinal bleeding and perforation, which may be fatal.

Therapeutic Uses of Diclac ID

Diclac ID contains diclofenac, a non-steroidal anti-inflammatory drug (NSAID), which is applied across domains where additional symptomatic support is needed. It is considered relevant in contexts marked by increased discomfort or tension, and its use is relevant when supportive symptom management is appropriate.

Main Uses and Benefits

Diclac ID is generally applied in addressing symptom clusters that may become intense or disruptive. It is commonly used to help address the signs and symptoms of conditions characterized by periods of heightened symptoms, including osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

In addition, it is commonly used to help with acute pain and provides supportive relief when symptoms interfere with routine activities, such as those associated with primary dysmenorrhea. It contributes to easing the overall symptom load and provides support during symptomatic episodes by easing distress, which may assist with maintaining functional stability.

Quick Fact: Relief for symptoms related to physical discomfort.

This medication may be applied in scenarios where symptoms escalate temporarily or when symptoms that interfere with daily functioning become more disruptive during flare-ups.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Diclac ID?

This medicine's eligibility is strictly defined by regulatory authorities based on age, pre-existing conditions, and physiological status. Diclac ID is intended only for use by adults.

Absolute Prohibitions (Contraindications)

Population/Condition	Status (Must NOT Use)
Age	Children and adolescents under 18 years of age.
Cardiovascular Disease	Established congestive heart failure (NYHA II–IV), ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.
GI Disease	Active gastrointestinal ulceration, bleeding, or perforation, or history of NSAID-related GI bleeding/perforation.
Organ Failure	Severe renal failure or severe hepatic failure.
Allergy	History of asthma, urticaria, or allergic reactions after taking aspirin or other NSAIDs.
Pregnancy	Women in the last trimester of pregnancy.

Restricted or Conditional Use

Patients with the following conditions require caution and close medical surveillance:

Mild to Moderate Organ Impairment: Patients with mild-to-moderate renal or hepatic impairment.
Elderly Patients: Use requires particular caution due to increased risk of serious gastrointestinal events.
Pregnancy (Mid-Term): Use is restricted between 20 and 30 weeks of gestation; use only when benefits outweigh risk.
Breastfeeding: Use is not recommended as diclofenac passes into breast milk.

What should I know about interactions with other medicines?

This section outlines the official interaction patterns for Diclac ID's active ingredient, diclofenac, as described in government regulatory documents.

Interaction Classifications

The interaction profile is structured around two key categories: contraindicated combinations and interactions requiring mandatory monitoring due to altered drug exposure.

Classification	Official Constraint	Example Interacting Agent
Contraindicated	Prohibited due to severe additive risk of gastrointestinal (GI) adverse events.	Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including Aspirin.
Requires Monitoring	Use requires monitoring of blood concentrations due to altered clearance.	Lithium, Digoxin, Methotrexate.

Official Interaction Statements

Co-administration with other systemic NSAIDs and high-dose Aspirin is formally documented as contraindicated. This restriction is based on the additive pharmacodynamic risk of serious GI bleeding and ulceration.

Diclofenac is documented to increase the plasma concentrations of Lithium, Digoxin, and Methotrexate by reducing their clearance, which necessitates monitoring of the co-administered drug's serum levels. The combination with potent CYP2C9 inhibitors, such as Voriconazole, increases diclofenac's exposure (AUC and C max) in the body.

Concomitant use with anticoagulants (e.g., Warfarin) and antiplatelet agents significantly increases the risk of serious bleeding due to an additive pharmacodynamic effect. Diclofenac may also reduce the antihypertensive effect of ACE Inhibitors, ARBs, and Diuretics, and increases the risk of renal impairment with these agents. Furthermore, the consumption of alcohol is restricted due to an increased risk of gastrointestinal adverse events. Regulatory warnings note that elderly patients face a greater risk for serious gastrointestinal events from these interactions.

Mechanism of Action

Molecular Suppression of Inflammatory Mediators

The active ingredient acts as a non-covalent inhibitor of the Cyclooxygenase ( COX) enzymes, particularly COX-2, thereby blocking the synthesis of Prostaglandins. This molecular blockade suppresses the production of these mediators, which are key physiological factors in vascular permeability and the sensitization of peripheral nociceptors.

Causal Chain: Nociception and Thermoregulation

By limiting Prostaglandin production, the mechanism reduces the chemical sensitization of peripheral nociceptors, resulting in a higher nociceptive activation threshold. A parallel action occurs within the hypothalamus, where the suppression of pyrogenic Prostaglandins modulates the thermal setpoint of the core body temperature.

Dual-Phase Control of Mechanistic Kinetics

Diclac ID’s modified-release formulation influences the temporal pattern of the mechanism. An immediate-release component rapidly inhibits the target enzymes, establishing prompt COX blockade, while the sustained-release component ensures a gradual, continuous flow of the active ingredient, maintaining consistent enzyme suppression throughout the dosing interval.

Dosage and Administration Information

How Diclac ID is Used: Administration Guidelines

The usage of Diclac ID, a diclofenac sodium modified-release tablet, follows specific parameters to ensure the correct administration of its dual-release formulation. These guidelines focus on the route, dose, frequency, and administration method, avoiding therapeutic claims.

Administration Scope

Instruction Entity	Administration Guideline
Route of administration	Oral (The approved route for this solid dosage form).
Standard Adult Dosing	The usual adult daily dose is 100 mg once daily. The total daily intake of diclofenac from all sources must not exceed 150 mg.
Timing in relation to meals	The tablet is preferably taken with or after food to aid administration.
Preparation requirements	The tablet must be swallowed whole with liquid; it should not be crushed, broken, or chewed.

Procedural and Duration Guidelines

Guideline Entity	Administration Rule
Frequency pattern	Once daily (q.d.), owing to the prolonged-release characteristics of the formulation.
Age-group rules	Older Adults should utilize the lowest effective dosage. The 100 mg modified-release tablet is not suitable for children and adolescents under 18 years.
Duration Principle	The drug is used at the lowest effective dose for the shortest duration possible to control symptoms. Treatment necessity is re-evaluated periodically.

Connection to the Overall Use Protocol

The instructions establish a structured once-daily oral regimen that requires the tablet's physical integrity to be preserved, ensuring the controlled release of the medicine is maintained. These guidelines define the standardized adult dosing and enforce limits on duration, ensuring the medicine is administered precisely.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diclac ID

Evidence for Use in Chronic Joint Conditions

This section will summarize the research base supporting the evaluation of the medicine for conditions like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS), detailing the types of randomized trials and systemic reviews that measured outcomes related to physical discomfort and functional changes in adult patients.

Research Structure for Osteoarthritis

Research evaluating the active ingredient in Diclac ID for Osteoarthritis involves numerous short-term, controlled clinical trials, many of which involved a placebo or another active treatment. These studies focused on adult populations, primarily those experiencing outcomes related to physical discomfort in joints like the hip and knee. Research examined patient-reported outcomes describing perceived discomfort and functional ability.

Studies reported measurements related to pain intensity and physical function. Network meta-analyses have also been used in research examining symptom patterns across a wide range of studies for this drug class.

Research Structure for Rheumatoid Arthritis and Ankylosing Spondylitis

For Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS), the research structure involved short-term randomized controlled trials applied in research contexts where symptoms were fluctuating or unstable. Researchers monitored outcomes such as the count of tender and swollen joints, as well as subjective measurements of disease activity and stiffness.

Studies observed symptomatic responses over defined time intervals. Findings describe measurements recorded during the study period, including the number of affected joints and overall functional status.

Evidence for Short-Term Acute Symptom Relief

The evidence base for the active ingredient studied for acute pain and primary dysmenorrhea is derived from a high volume of very short-term, high-quality controlled trials. These studies were relevant in trials assessing short-term or episodic symptom patterns, primarily involving adults experiencing episodes where symptoms become more noticeable.

Research explored short-term symptom changes, with researchers measuring the total magnitude and speed of pain change over periods as short as 24 hours to three days. Findings consistently describe patterns observed in the studies regarding measured symptomatic change following administration.

Current Research Gaps and Uncertainties

Research highlights what is known and what is still uncertain regarding the evidence for this medicine. The existing research, while extensive, contains several gaps:

Comparative evidence is lacking for a direct comparison of Diclac ID's specific dual-release technology against other generic or modified-release diclofenac available formulations.
The research focuses primarily on symptomatic relief; it does not address whether the medicine influences the long-term progression of underlying joint diseases.
Long-term outcomes are not fully established based on dedicated efficacy trials.

Key Studies & References Extended-release diclofenac formulations for pain and inflammation (Review on Formulations/Kinetics)

Frequently Asked Questions (FAQ)

Common questions about Diclac ID (FAQ)

Q: What is the difference between Diclac ID and regular Diclac?

According to official product information, Diclac ID is a specific modified-release tablet formulation of the active ingredient, diclofenac. It uses a dual-release technology which is designed to provide both immediate relief and sustained action. This design aims to maintain consistent levels of the active ingredient in the body.

Q: How quickly does Diclac ID start working?

Official information indicates the tablet contains an immediate-release component, which is intended to provide prompt inhibition of the target enzymes. However, it is noted that taking the medication with food may delay the full absorption of the medicine by up to several hours.

Q: Can Diclac ID be taken by someone with high blood pressure?

Regulatory documents note that patients with a history of high blood pressure (hypertension) or other cardiovascular risk factors require careful consideration, and monitoring may be necessary during treatment. This is because the medicine, like others in its class, may potentially cause fluid retention and an increase in blood pressure.

Q: Are there any food restrictions when taking Diclac ID?

The administration guidelines state the tablet is preferably taken with or after food to aid administration. Additionally, official warnings note that consuming alcohol while using this medicine is restricted, as it significantly increases the risk of serious gastrointestinal side effects.

Q: Can Diclac ID affect my sleep?

Official documents list that sleep-related issues are possible side effects. These include feeling drowsy or experiencing insomnia (difficulty sleeping) among the reported adverse effects on the nervous system.

Q: Does Diclac ID interact with common vitamins or supplements?

While the official interaction profile primarily lists prescription medications, it does not explicitly name all common vitamins or supplements. Regulatory guidance notes the importance of informing a healthcare provider about all medicines, herbal remedies, vitamins, or supplements used.

Q: Is Diclac ID the same as diclofenac?

No, they are not exactly the same. Diclofenac is the active ingredient found in the medicine. Diclac ID is the specific trade name for a product that utilizes this active ingredient in a unique modified-release tablet formulation.

Q: How is Diclac ID cleared from the body?

The active ingredient is removed from the body primarily by being metabolized in the liver. This process involves specific enzymes and results in the formation of inactive substances. These substances are then removed from the body through urine and bile.

Q: Does taking Diclac ID long-term cause any problems?

Official regulatory documents issue a warning that the risk of serious adverse events, such as a heart attack, stroke, or severe gastrointestinal issues like bleeding, may increase with both the dose and the duration of use. Official regulatory guidance emphasizes using the product at the lowest effective dose for the shortest duration possible.

Q: Can Diclac ID cause changes in mood or behavior?

Official product information lists that mood and behavior changes are possible, though they are considered less common nervous system effects. Reported adverse reactions in this category include anxiety, confusion, depression, and changes in dreaming patterns.

Q: Why is Diclac ID sometimes preferred for chronic conditions?

The design of Diclac ID, which utilizes a prolonged-release characteristic, allows for an approved once-daily dosing frequency. This is often cited in regulatory documents as a way to allow for sustained drug levels in the body, which can be useful when addressing chronic symptoms.

Q: What are the signs of a serious allergic reaction to Diclac ID?

Official warnings describe that signs of a serious allergic reaction can include swelling of the face, lips, or mouth (angioedema), difficulty breathing, or a severe skin rash. It is also noted that serious reactions may be accompanied by symptoms like chest pain.

Q: Is Diclac ID prescribed for headaches or migraines?

The active ingredient, diclofenac, is used to treat various forms of acute pain, and certain specific formulations are indicated for migraine attacks. However, the official prescribing indications for Diclac ID are defined by the approved uses listed on the medicine's label.

Q: Does Diclac ID affect fertility?

Official regulatory information states that, for women, the medicine may impair fertility and is therefore not recommended for those who are trying to become pregnant. This potential effect on fertility is generally considered to be reversible once the use of the drug is stopped.

Q: Is it common for Diclac ID to cause fluid retention?

Official documents report that fluid retention and oedema (swelling) have been associated with this medicine, as is true for the NSAID class generally. Caution is advised for individuals with conditions like impaired heart or kidney function, or a history of high blood pressure.

Q: Does Diclac ID interact with herbal remedies like St. John's Wort?

Diclofenac is metabolized in the body using the CYP2C9 enzyme system. Some herbal remedies, such as St. John’s Wort, can influence the activity of this enzyme. This means that such remedies could theoretically change the amount of diclofenac present in the blood, potentially altering the drug's effects.

How should Diclac ID be stored and disposed of?

Official Storage and Disposal Instructions for Diclac ID

Diclac ID tablets must be stored according to specific regulatory requirements to ensure stability and safety.

Storage Conditions

Requirement	Official Instruction
Temperature	Do not store above 25 C
Protection	Keep in a cool, dry place, protected from moisture and high heat
Packaging	Keep in the original package until use
Safety	Store out of the sight and reach of children

Disposal Instructions

Expired or unused Diclac ID must be disposed of properly to protect the environment. The medicine must not be thrown away via wastewater or with household waste. For proper disposal instructions, consult a pharmacist. This process ensures compliance with pharmaceutical waste management guidelines.

Diclac ID